20/20 Biolabs, Inc. Common Stock (AIDX) — Cash Flow Reinvestment Rate
20/20 Biolabs, Inc. Common Stock (AIDX) has a Cash Flow Reinvestment Rate of 0.05x as of December 2022, reinvesting $261.79K (capex $261.79K ) from operating cash flow of $5.80 Million. See AIDX free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
20/20 Biolabs, Inc. Common Stock Cash Flow Reinvestment Rate (2022–2022)
Historical reinvestment intensity for 20/20 Biolabs, Inc. Common Stock across 1 annual periods. For the full cash flow conversion analysis, see 20/20 Biolabs, Inc. Common Stock cash conversion from operations.
Annual Cash Flow Reinvestment Rate for 20/20 Biolabs, Inc. Common Stock (2022–2022)
Year-by-year capital reinvestment analysis for 20/20 Biolabs, Inc. Common Stock. See 20/20 Biolabs, Inc. Common Stock financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 0.05x | $261.79K | $5.80 Million | $261.79K | — |